Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes
about
Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?Early detection of sensorineural hearing loss in Muckle-Wells-syndromeChronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a reviewEvasion of inflammasome activation by microbial pathogensInterleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia.Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation.Early investigational drugs for hearing loss.An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndromeConstitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice.IL-1 blockade in autoinflammatory syndromes.A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1β.Neonatal treatment of CINCA syndrome.Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS).Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesAn expanding role for interleukin-1 blockade from gout to cancer.NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanismsThe role of IL-1β in the bone loss during rheumatic diseases.Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.New tricks from an old dog: mitochondrial redox signaling in cellular inflammation.The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes.Monogenic autoinflammatory diseases: concept and clinical manifestations.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).Febrile infection-related epilepsy syndrome treated with anakinraTreating inflammation by blocking interleukin-1 in humans.Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.Statistical challenges in the evaluation of treatments for small patient populations.Current immunotherapy in rheumatoid arthritis.Anakinra for cryopyrin-associated periodic syndrome.Monogenic autoinflammatory diseases.Protective and detrimental roles of inflammasomes in disease.CAPS--pathogenesis, presentation and treatment of an autoinflammatory disease.Recommendations for the management of autoinflammatory diseases.Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes.
P2860
Q27002805-DD648CDB-6C20-487A-BC92-105D571971E8Q27303524-A2FDC5F4-9DB2-4784-B010-51657B2F1885Q28066948-AA88816F-DE06-4550-8450-9FF94FC060F4Q28082757-CFA2646E-F01B-40F4-9A14-B0A942EDB083Q30544045-149E9AB1-72F1-4D13-A66C-DBA1D172AD68Q30750457-67ED6C56-6FBD-4C3C-ACDB-8DD68653C9C3Q33847686-C5D2C2A7-46BF-4B72-B31E-1A30205CA6C7Q34254955-BA5295C8-D0F5-467E-A322-B430F9ECD560Q34257004-7DD8D859-25C8-43A0-BE56-EB4845C35865Q34262561-818FB167-8603-4615-87C3-32861C10A2ABQ34423486-9ED2F08E-0111-44CB-A8E3-01F181DB5C06Q34472457-F59FA839-C451-4636-B2F9-79A1C8CB04A2Q34504994-421B23F0-37ED-4DE6-B9AA-FBECF364AEEFQ34908472-FE39CC5C-6215-4D69-95D2-E85D7BA29EAAQ35071366-0EA2860C-D701-486B-B662-8622DA45EF58Q35122583-6ACA0622-7241-47D5-9F11-91B7FB2B67D5Q35133812-26F147D0-DD28-46A8-8399-ACE51123973CQ35219001-E82DF2CF-498E-48D0-B28F-ECB4B4D831B4Q35410664-0F2F721D-F329-4CC1-AE13-7D74148319F7Q35540844-2F997FAE-87DE-4C85-9384-ED01D6E4FD0DQ36041225-3C25E1A1-9380-4E24-ADCE-811F7DF5B389Q36816872-2140E2A6-F32A-4392-9AB8-F51908F0A2A9Q36834142-42D091AD-549C-4CF9-BBF2-FD168F63373BQ36903288-5F6DA376-7A3A-499D-B873-B6FCE48E3419Q37118963-95D9D862-5634-4754-977E-7B4DFBF611E3Q37162157-594A9AE4-1357-46E3-A57B-4716DA15BBD5Q37270409-675B81C8-D94B-43B0-85DF-F9F4272EB7B3Q37466515-54EE1A48-0D3C-47A5-BEC5-C10C934D7CC5Q37572983-9A2DB046-06CF-426D-8C72-C0B8CDF5EEECQ37579506-A9A7E5E2-90FD-4104-B37E-13362A41519FQ37636664-752B1275-CCF7-4595-B9F2-10DF11D455BFQ37719673-D54D0637-BEFE-46A4-9062-FC834E5B524DQ38093778-268B265A-3CFF-44FD-B118-0633D304ADB9Q38133655-3005BBBE-9BAA-4FE1-9B6E-335E613E8B97Q38168948-B3372E7F-0D6E-44BC-979B-C3E0F7DF1DF4Q38211947-02ABE2DE-49E9-4DF4-9299-F00284A65DF8Q38431249-194DA1C5-C47F-4807-8F8C-893AB7E92EC8Q38473823-2806E97D-A6E0-4220-9F89-78BDA384C78FQ38537504-EC38811B-E265-4819-8199-DCC4E62645BEQ38542409-14BB5575-A979-40BF-9DDF-30FBD38A27EF
P2860
Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Sustained response and prevent ...... three- and five-year outcomes
@ast
Sustained response and prevent ...... three- and five-year outcomes
@en
type
label
Sustained response and prevent ...... three- and five-year outcomes
@ast
Sustained response and prevent ...... three- and five-year outcomes
@en
prefLabel
Sustained response and prevent ...... three- and five-year outcomes
@ast
Sustained response and prevent ...... three- and five-year outcomes
@en
P2093
P2860
P356
P1476
Sustained response and prevent ...... three- and five-year outcomes
@en
P2093
Brigitte Widemann
Cailin H Sibley
Carmen C Brewer
Christopher Snyder
Christopher Zalewski
Dawn Chapelle
Deborah L Stone
Edythe A Wiggs
Frank Pucino
H Jeffrey Kim
P2860
P304
P356
10.1002/ART.34409
P577
2012-07-01T00:00:00Z